BeOne Medicines (NASDAQ:ONC) SVP Sells $156,928.20 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 590 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $265.98, for a total value of $156,928.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total value of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Trading Up 2.8%

Shares of NASDAQ ONC traded up $7.47 on Thursday, reaching $270.15. 367,884 shares of the company traded hands, compared to its average volume of 260,552. The stock has a market capitalization of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average of $296.83 and a 200 day moving average of $312.94.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. On average, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ONC. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Royal Bank Of Canada boosted their price target on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Morgan Stanley restated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Wells Fargo & Company initiated coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Finally, Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $390.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Empowered Funds LLC purchased a new position in BeOne Medicines in the first quarter valued at about $201,000. Bank of America Corp DE boosted its position in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after buying an additional 26,441 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of BeOne Medicines in the first quarter valued at about $3,475,000. EverSource Wealth Advisors LLC grew its stake in shares of BeOne Medicines by 16.4% in the first quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after buying an additional 52 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of BeOne Medicines by 3.5% during the 1st quarter. Royal Bank of Canada now owns 70,391 shares of the company’s stock valued at $20,905,000 after buying an additional 2,399 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.